ELVNEnliven Therapeutics, Inc.同业对比
Enliven Therapeutics, Inc. 与Pharmaceutical Preparations的逐项对比:市值、估值、增长、盈利能力、质量与总回报,以及在同业组内的排名。所有数值均由引擎从 SEC 申报与延迟行情计算,排名仅为组内排序位置 —— 描述性数据,非投资建议。
完整同业对比
同业组:同 SIC 行业分类 (Pharmaceutical Preparations)| 公司 | 市值 | 市盈率(TTM) | 市净率 | 市销率 | 营收同比增长 | 净利同比增长 | 息税前利润率 | 净资产收益率 | 投入资本回报率 | 皮氏 F 值 | 一年总回报 | 股息率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ELVN本股 | $3.7B#8 | — | 4.1x#5 | — | — | -16.5%#8 | — | -11.6%#9 | — | — | 164.8%#5 | — |
| PBLS | $4.9B#1 | — | 4.7x#7 | — | — | — | — | 0.0%#3 | — | — | — | — |
| ACAD | $4.7B#2 | 12.3x#1 | 3.6x#3 | 4.4x#2 | 11.9%#6 | 73.0%#2 | 9.8%#2 | 29.9%#1 | 11.4%#1 | — | 13.0%#13 | — |
| MANE | $4.5B#3 | — | 5.6x#10 | — | — | -164.3%#14 | — | -8.6%#6 | — | — | — | — |
| TNGX | $4.1B#4 | — | 4.0x#4 | 65.0x#6 | 48.3%#5 | 22.0%#6 | -178.4%#5 | -9.9%#8 | — | — | 215.6%#2 | — |
| ABCL | $3.9B#5 | — | 4.4x#6 | 52.0x#5 | 160.6%#2 | 10.1%#7 | -289.0%#6 | -16.3%#10 | -28.0%#4 | — | 179.4%#3 | — |
| AMLX | $3.8B#6 | — | 15.7x#15 | — | -100.0%#10 | 52.0%#4 | — | -60.5%#13 | — | — | 164.2%#6 | — |
| IDYA | $3.7B#7 | — | 3.1x#1 | 17.1x#4 | 3024.4%#1 | 58.6%#3 | -72.8%#4 | -9.5%#7 | — | — | 58.7%#8 | — |
| OGN | $3.6B#9 | 17.5x#2 | 3.6x#2 | 0.6x#1 | -2.9%#7 | -78.4%#12 | 14.9%#1 | 18.6%#2 | 4.9%#2 | 5#1 | 34.1%#11 | 2.5%#1 |
| VKTX | $3.4B#10 | — | 8.4x#13 | — | — | -227.1%#15 | — | -88.1%#15 | — | — | 27.5%#12 | — |
| DYN | $3.3B#11 | — | 4.7x#8 | — | — | -40.6%#11 | — | -0.0%#4 | -1301.5%#8 | — | 34.5%#10 | — |
| RCUS | $3.3B#12 | — | 7.0x#11 | 98.5x#7 | -35.3%#9 | -24.7%#9 | -1169.7%#8 | -76.1%#14 | -93.0%#7 | — | — | — |
| ARQT | $3.1B#13 | 113.7x#3 | 14.3x#14 | 8.4x#3 | 91.3%#4 | 88.5%#1 | -3.3%#3 | -7.3%#5 | -4.1%#3 | — | 45.9%#9 | — |
| MBX | $3.1B#14 | — | 7.5x#12 | — | — | -40.5%#10 | — | -21.2%#11 | — | — | 538.2%#1 | — |
| PGEN | $2.7B#15 | — | 63.0x#16 | 283.6x#8 | 146.7%#3 | -98.6%#13 | -1141.1%#7 | -575.1%#16 | -91.2%#6 | — | 101.3%#7 | — |
| IMNM | $2.7B#16 | — | 5.2x#9 | 392.2x#9 | -23.2%#8 | 27.5%#5 | -3228.8%#9 | -40.4%#12 | -72.8%#5 | — | 167.1%#4 | — |
数值来自 SEC 申报与延迟行情;排名仅为该组内的排序位置 —— 描述性数据,不构成评级或建议。 数据构建于 2026-09-17。
数据来自 SEC XBRL 申报与延迟行情 · 排名为组内排序 · 仅供参考 · 非投资建议